NASDAQ:ABUS - Arbutus Biopharma Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $11.70 +0.20 (+1.74 %) (As of 07/16/2018 04:59 AM ET)Previous Close$11.70Today's Range$11.30 - $11.9552-Week Range$3.20 - $12.05Volume822,803 shsAverage Volume787,358 shsMarket Capitalization$645.47 millionP/E Ratio-6.54Dividend YieldN/ABeta0.99 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada. Receive ABUS News and Ratings via Email Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ABUS CUSIPN/A Webwww.tekmirapharm.com Phone604-419-3200 Debt Debt-to-Equity Ratio0.01 Current Ratio16.86 Quick Ratio16.86 Price-To-Earnings Trailing P/E Ratio-6.54 Forward P/E Ratio-7.85 P/E GrowthN/A Sales & Book Value Annual Sales$10.70 million Price / Sales60.33 Cash FlowN/A Price / CashN/A Book Value$2.41 per share Price / Book4.85 Profitability EPS (Most Recent Fiscal Year)($1.79) Net Income$-84,410,000.00 Net Margins-705.09% Return on Equity-61.50% Return on Assets-36.20% Miscellaneous Employees130 Outstanding Shares55,170,000Market Cap$645.47 Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions What is Arbutus Biopharma's stock symbol? Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS." How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Corp (NASDAQ:ABUS) posted its quarterly earnings data on Thursday, May, 3rd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.03. The biopharmaceutical company earned $1.40 million during the quarter. Arbutus Biopharma had a negative return on equity of 61.50% and a negative net margin of 705.09%. View Arbutus Biopharma's Earnings History. When is Arbutus Biopharma's next earnings date? Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Arbutus Biopharma. What price target have analysts set for ABUS? 5 analysts have issued 1 year price objectives for Arbutus Biopharma's stock. Their predictions range from $5.00 to $13.00. On average, they anticipate Arbutus Biopharma's share price to reach $8.20 in the next twelve months. This suggests that the stock has a possible downside of 29.9%. View Analyst Ratings for Arbutus Biopharma. What is the consensus analysts' recommendation for Arbutus Biopharma? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Are investors shorting Arbutus Biopharma? Arbutus Biopharma saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 2,891,777 shares, an increase of 281.0% from the June 15th total of 759,060 shares. Based on an average daily trading volume, of 716,059 shares, the days-to-cover ratio is presently 4.0 days. Currently, 8.3% of the company's shares are sold short. View Arbutus Biopharma's Current Options Chain. Who are some of Arbutus Biopharma's key competitors? Some companies that are related to Arbutus Biopharma include Clovis Oncology (CLVS), Endo International (ENDP), TESARO (TSRO), Spectrum Pharmaceuticals (SPPI), Akcea Therapeutics (AKCA), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Myokardia (MYOK) and Prestige Brands (PBH). Who are Arbutus Biopharma's key executives? Arbutus Biopharma's management team includes the folowing people: Dr. Mark Joseph Murray, Pres, CEO & Director (Age 69)Dr. Michael J. Sofia, Chief Scientific Officer (Age 60)Dr. Elizabeth Howard, Exec. VP & Gen. Counsel (Age 64)Mr. Bruce G. Cousins, Consultant (Age 57)Mr. David C. Hastings, Chief Financial Officer (Age 57) Has Arbutus Biopharma been receiving favorable news coverage? Headlines about ABUS stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Arbutus Biopharma earned a news sentiment score of 0.10 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 43.26 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. How do I buy shares of Arbutus Biopharma? Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Arbutus Biopharma's stock price today? One share of ABUS stock can currently be purchased for approximately $11.70. How big of a company is Arbutus Biopharma? Arbutus Biopharma has a market capitalization of $645.47 million and generates $10.70 million in revenue each year. The biopharmaceutical company earns $-84,410,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. Arbutus Biopharma employs 130 workers across the globe. How can I contact Arbutus Biopharma? Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected] MarketBeat Community Rating for Arbutus Biopharma (NASDAQ ABUS)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 293 (Vote Outperform)Underperform Votes: 197 (Vote Underperform)Total Votes: 490MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?